AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36054449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 33439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reporting with digital solutions
Number of subjects: 70
Study 33439274 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting without structured solutions
Number of subjects: 70
Study 33439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of reports
Number of subjects: 70
Study 33439274 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual departments
Number of subjects: 70
Study 35727760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in SAVOR-TIMI 53 trial
Number of subjects: 10555
Study 35727760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in CPRD-DM2 cohort
Number of subjects: 10555
Study 35727760 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower than median bilirubin levels in CPRD-HT cohort
Number of subjects: 10555
Study 33124470 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental condition (watching a video of a socially anxious presenter)
Number of subjects: 128
Study 33124470 — intervention group
Group type: COMPARATOR
Intervention: Control condition (watching a video of a nonanxious presenter)
Number of subjects: 128
Study 34425554 — intervention group
Group type: EXPERIMENTAL
Intervention: SC79 injection at 0.02 mg/kg bodyweight
Number of subjects: 78
Study 34425554 — intervention group
Group type: EXPERIMENTAL
Intervention: SC79 injection at 0.04 mg/kg bodyweight
Number of subjects: 78
Study 34425554 — intervention group
Group type: COMPARATOR
Intervention: SC79 injection at 0 mg/kg bodyweight (control)
Number of subjects: 78
Study 34425554 — intervention group
Group type: EXPERIMENTAL
Intervention: SC79 injection
Number of subjects: 78
Study 32043762 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional oral care (POC)
Number of subjects: 175
Study 32043762 — intervention group
Group type: COMPARATOR
Intervention: Control (brushing teeth and gargling with 0.9% sodium chloride solution or water)
Number of subjects: 175
Study 34294123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillotomy
Number of subjects: 454
Study 34294123 — intervention group
Group type: COMPARATOR
Intervention: Tonsillectomy
Number of subjects: 454
Study 36286977 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with specialized food (2 portions of SPP2 a day)
Number of subjects: 0
Study 36286977 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric diet alone (ICD)
Number of subjects: 0
Study 33678517 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizons + Group Motivational Enhancement Therapy
Number of subjects: 560
Study 33678517 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizons
Number of subjects: 560
Study 35108669 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyhexamethylene biguanide (PHMB)
Number of subjects: 14
Study 35108669 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 37151132 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 0
Study 37151132 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 0
Study 37151132 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 34454754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milk replacer (HF; 39.9% lactose, 24.6% crude fat, and 24.0% crude protein of dry matter)
Number of subjects: 34
Study 34454754 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat milk replacer (HF)
Number of subjects: 34
Study 34454754 — intervention group
Group type: COMPARATOR
Intervention: High-lactose milk replacer (46.1% lactose, 18.0% crude fat, and 23.9% crude protein of dry matter)
Number of subjects: 34
Study 35309062 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral concentric‐only (CONC) training
Number of subjects: 60
Study 35309062 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric‐only (ECC) training
Number of subjects: 60
Study 35309062 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric–eccentric (TRAD) training
Number of subjects: 60
Study 35309062 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 60
Study 34787844 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic VSL#3®
Number of subjects: 0
Study 34787844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33737628 — intervention group
Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeast (C. tropicalis KKU20)
Number of subjects: 6
Study 33737628 — intervention group
Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeast (P. kudriavzevii KKU20)
Number of subjects: 6
Study 33737628 — intervention group
Group type: COMPARATOR
Intervention: Crabtree-positive yeast (S. cerevisiae)
Number of subjects: 6
Study 33737628 — intervention group
Group type: EXPERIMENTAL
Intervention: Crabtree-negative yeasts (P. kudriavzevii KKU20 and C. tropicalis KKU20)
Number of subjects: 6
Study 33737628 — intervention group
Group type: EXPERIMENTAL
Intervention: C. tropicalis KKU20
Number of subjects: 6
Study 32723609 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic adrenalectomy (RA)
Number of subjects: 140
Study 32723609 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adrenalectomy (LA)
Number of subjects: 140
Study 36443678 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural network (multi-layer perceptron)
Number of subjects: 58
Study 32915962 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Clust algorithm for clustering genetic variants
Number of subjects: 0
Study 32915962 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-Clust algorithm
Number of subjects: 0
Study 32915962 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants in the cluster with a negative effect of blood pressure
Number of subjects: 0
Study 36093398 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP future care
Number of subjects: 163
Study 36093398 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 163
Study 33296688 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose NOACs
Number of subjects: 77282
Study 33296688 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose NOACs
Number of subjects: 77282
Study 33296688 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 77282
Study 32497453 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group
Number of subjects: 132
Study 32497453 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative group
Number of subjects: 132
Study 32497453 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 132
Study 34737220 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids (OCS) treatment
Number of subjects: 525
Study 34737220 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma proteomic panel
Number of subjects: 525
Study 34737220 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus clustering of U-BIOPRED protein data
Number of subjects: 525
Study 33130236 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad consent for randomization shortly after cohort enrollment
Number of subjects: 610
Study 33130236 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad consent for randomization after randomization to an intervention (12-18 months after cohort enrollment)
Number of subjects: 610
Study 33130236 — intervention group
Group type: COMPARATOR
Intervention: Patients not selected for interventions (1-6 months after cohort enrollment)
Number of subjects: 610
Study 33172395 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA + CBD stenting
Number of subjects: 64
Study 33172395 — intervention group
Group type: COMPARATOR
Intervention: CBD stenting (control)
Number of subjects: 64
Study 34939318 — intervention group
Group type: EXPERIMENTAL
Intervention: Advised to hand express for 10 minutes twice daily until birth (n=319)
Number of subjects: 635
Study 34939318 — intervention group
Group type: COMPARATOR
Intervention: Usual care (not expressing, n=316)
Number of subjects: 635
Study 32024506 — intervention group
Group type: EXPERIMENTAL
Intervention: You-CAN led by school staff
Number of subjects: 3
Study 32024506 — intervention group
Group type: EXPERIMENTAL
Intervention: You-CAN led by school staff and research team
Number of subjects: 3
Study 32024506 — intervention group
Group type: COMPARATOR
Intervention: Untreated comparison group
Number of subjects: 3
Study 32955966 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Employment Success Tool (IESTTM)
Number of subjects: 29
Study 33909947 — intervention group
Group type: EXPERIMENTAL
Intervention: insoluble cereal fibre
Number of subjects: 180
Study 33909947 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 36030971 — intervention group
Group type: EXPERIMENTAL
Intervention: APEX: 5.25%‐6% NaOCl, 5.25%‐6% NaOCl + 17% EDTA and calcium hydroxide
Number of subjects: 97
Study 36030971 — intervention group
Group type: EXPERIMENTAL
Intervention: REGEN: 1.25% NaOCl, 17% EDTA, and 0.1 mg/mL triple antibiotic paste (TAP)
Number of subjects: 97
Study 36030971 — intervention group
Group type: EXPERIMENTAL
Intervention: REVASC: 5.25% NaOCl, saline, and 1 g/mL TAP
Number of subjects: 97
Study 33242163 — intervention group
Group type: EXPERIMENTAL
Intervention: Loco-regional treatment (LRT)
Number of subjects: 81
Study 33242163 — intervention group
Group type: COMPARATOR
Intervention: Systemic treatment (ST)
Number of subjects: 81
Study 33242163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage I–III BC patients
Number of subjects: 81
Study 32400210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesplora Aquarium test (experimental group)
Number of subjects: 120
Study 32400210 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 32500212 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin (10, 20, 30 mg/70 kg)
Number of subjects: 20
Study 32500212 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DXM) (400 mg/70 kg)
Number of subjects: 20
Study 32500212 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 36277940 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized home-based support including monthly visits focused on nutritional counseling and pregnancy monitoring.
Number of subjects: 617
Study 36277940 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving prenatal care according to national program guidelines.
Number of subjects: 617
Study 33154182 — intervention group
Group type: EXPERIMENTAL
Intervention: Listen-In therapy (self-led therapy app)
Number of subjects: 35
Study 33154182 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 35
Study 36280985 — intervention group
Group type: EXPERIMENTAL
Intervention: Positional release of subscapularis technique (Group A)
Number of subjects: 34
Study 36280985 — intervention group
Group type: COMPARATOR
Intervention: Ola Grimsby technique (Group B)
Number of subjects: 34
Study 33910395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-controlled feedback (SC)
Number of subjects: 24
Study 33910395 — intervention group
Group type: COMPARATOR
Intervention: Yoked feedback (YK)
Number of subjects: 24
Study 36102434 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy (LSG)
Number of subjects: 36
Study 36102434 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (LRYGB)
Number of subjects: 36
Study 34560869 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 62
Study 34560869 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 62
Study 34560869 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 62
Study 34560869 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP
Number of subjects: 62
Study 32087282 — intervention group
Group type: EXPERIMENTAL
Intervention: Down-Regulation
Number of subjects: 76
Study 32087282 — intervention group
Group type: EXPERIMENTAL
Intervention: Distress Tolerance
Number of subjects: 76
Study 32087282 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional Awareness
Number of subjects: 76
Study 32087282 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 76
Study 33581839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Delirium Prediction (MDP) tool using derivation cohort
Number of subjects: 120764
Study 33581839 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Delirium Prediction (MDP) tool using validation cohort
Number of subjects: 120764
Study 33581839 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk classification based on predicted probability of delirium
Number of subjects: 120764
Study 33269836 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (once daily for 10 courses, 6 consecutive times each course) at points Quchi (LI11), Zusanli (ST36), Taichong (LR3), Hegu (LI4), Shenshu (BL23), Geshu (BL17), and Dazhui (GV14)
Number of subjects: 120
Study 33269836 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (10-15 mg/time, once a week for 10 weeks)
Number of subjects: 120
Study 33757591 — intervention group
Group type: EXPERIMENTAL
Intervention: Motherly smartphone app with behavioral activation (BA) and brief CBT
Number of subjects: 70
Study 33757591 — intervention group
Group type: COMPARATOR
Intervention: Simplified version of the Motherly app (active control)
Number of subjects: 70
Study 33045193 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-fluid HIV self-tests distributed during home visits; one present household member trained on self-test use.
Number of subjects: 7816
Study 33045193 — intervention group
Group type: COMPARATOR
Intervention: Control group referred absent or declining household members to the clinic for HIV testing.
Number of subjects: 7816
Study 33045193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with oral-fluid HIV self-tests.
Number of subjects: 7816
Study 33045193 — intervention group
Group type: COMPARATOR
Intervention: Control group without self-tests.
Number of subjects: 7816
Study 32291095 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-modified moisturizer
Number of subjects: 36
Study 32291095 — intervention group
Group type: COMPARATOR
Intervention: Standard moisturizer
Number of subjects: 36
Study 35588553 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo intervention (sham analgesic cream) applied before and after heat stimulations
Number of subjects: 19
Study 35588553 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat stimulations applied to the desired and undesired leg
Number of subjects: 19
Study 32571773 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus oseltamivir
Number of subjects: 308
Study 32571773 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 308
Study 35093029 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g oral dose of intra-partum azithromycin
Number of subjects: 829
Study 35093029 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 33539944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib (60 mg, D3-D23 of each 28-day cycle) plus paclitaxel (80 mg/m2, D1, 8, and 15)
Number of subjects: 0
Study 33539944 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel (80 mg/m2, D1, 8, and 15)
Number of subjects: 0
Study 33539944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib plus atezolizumab (840 mg, D1 and D15) and paclitaxel
Number of subjects: 0
Study 33539944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib plus atezolizumab (840 mg, D1 and D15) and nab-paclitaxel (100 mg/m2, D1, D8, and D15)
Number of subjects: 0
Study 32888898 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for knee osteoarthritis (8 weeks duration)
Number of subjects: 80
Study 32888898 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 33826756 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized studies
Number of subjects: 0
Study 33421263 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge Summaries (DS)
Number of subjects: 100
Study 32238947 — intervention group
Group type: EXPERIMENTAL
Intervention: WellNet (patient-centered medical home model)
Number of subjects: 5684
Study 32238947 — intervention group
Group type: COMPARATOR
Intervention: Standard care (usual care)
Number of subjects: 5684
Study 36351725 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI arm
Number of subjects: 525
Study 36351725 — intervention group
Group type: COMPARATOR
Intervention: PSA arm
Number of subjects: 525
Study 35488544 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV vaccine administered at 0, 1, and 6 months
Number of subjects: 105
Study 35488544 — intervention group
Group type: COMPARATOR
Intervention: Routine diagnosis and treatment without vaccine (Control)
Number of subjects: 105
Study 35488544 — intervention group
Group type: EXPERIMENTAL
Intervention: HEV vaccine (3 doses)
Number of subjects: 105
Study 32304484 — intervention group
Group type: EXPERIMENTAL
Intervention: AutonoMe (system A)
Number of subjects: 0
Study 32304484 — intervention group
Group type: EXPERIMENTAL
Intervention: UltraSert (system U)
Number of subjects: 0
Study 32304484 — intervention group
Group type: COMPARATOR
Intervention: Tecnis iTec (system T)
Number of subjects: 0
Study 32304484 — intervention group
Group type: COMPARATOR
Intervention: Vivinex iSert (system V)
Number of subjects: 0
Study 35089384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric wall squat (IWS)
Number of subjects: 26
Study 35089384 — intervention group
Group type: COMPARATOR
Intervention: Isometric handgrip (IHG)
Number of subjects: 26
Study 34274786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use for more than 180 days
Number of subjects: 0
Study 34274786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use of 180 > cDDD ? 28
Number of subjects: 0
Study 34274786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants (ATDs) use of cDDD ? 180
Number of subjects: 0
Study 34274786 — intervention group
Group type: COMPARATOR
Intervention: Bupropion
Number of subjects: 0
Study 33844622 — intervention group
Group type: COMPARATOR
Intervention: Expectation Only
Number of subjects: 76
Study 33844622 — intervention group
Group type: EXPERIMENTAL
Intervention: Empathic Support + Expectation
Number of subjects: 76
Study 33844622 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study 32519238 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets
Number of subjects: 22
Study 32519238 — intervention group
Group type: COMPARATOR
Intervention: Conventional brackets
Number of subjects: 22
Study 32883241 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-gauge needle
Number of subjects: 162
Study 32883241 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge needle
Number of subjects: 162
Study 35438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction models based on serum biomarkers for sarcopenia
Number of subjects: 212
Study 35438829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C, estimated glomerular filtration rate based on cystatin C, sarcopenia index, new sarcopenia index, haemoglobin, and albumin levels
Number of subjects: 212
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller global cortical thickness
Number of subjects: 350
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller mean thickness in widespread regions
Number of subjects: 350
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller thickness in a few frontal and temporal regions
Number of subjects: 350
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Right cuneus thickness
Number of subjects: 350
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller thickness ratio in frontal and temporal regions
Number of subjects: 350
Study 32384143 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater thickness ratio in the anterior cingulate
Number of subjects: 350
Study 35986273 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported clinical decision support system for polypharmacy management
Number of subjects: 198
Study 33278331 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable Injector (WI) delivering 5 mL subcutaneous placebo injections
Number of subjects: 52
Study 33028588 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval training (HIIT, n=400)
Number of subjects: 1567
Study 33028588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training (MICT, n=387)
Number of subjects: 1567
Study 33028588 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=780)
Number of subjects: 1567
Study 33028588 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT compared with MICT
Number of subjects: 1567
Study 36036856 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐ASA (phospholipid‐aspirin liquid filled capsules)
Number of subjects: 36
Study 36036856 — intervention group
Group type: EXPERIMENTAL
Intervention: PL‐ASA
Number of subjects: 36
Study 36036856 — intervention group
Group type: COMPARATOR
Intervention: EC‐ASA (low dose enteric-coated aspirin)
Number of subjects: 36
Study 36036856 — intervention group
Group type: COMPARATOR
Intervention: EC‐ASA
Number of subjects: 36
Study 32843241 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash plus intervention
Number of subjects: 1933
Study 35726631 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 2204
Study 35726631 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 2204
Study 32023293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with dihydroartemisinin-piperaquine and single low-dose primaquine
Number of subjects: 3790
Study 36430097 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based mindfulness intervention (YBM)
Number of subjects: 0
Study 36430097 — intervention group
Group type: COMPARATOR
Intervention: Psycho-educational sessions (Control)
Number of subjects: 0
Study 32297786 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg long‐acting methylphenidate
Number of subjects: 82
Study 32297786 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg long‐acting methylphenidate
Number of subjects: 82
Study 32297786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82